1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Biologics Development
  6.  » A Strategy to Remove Formulation Development from the Critical Path

A Strategy to Remove Formulation Development from the Critical Path

Summary: Biopharmaceuticals tend to be highly unstable. Therefore, as the product development program progresses to phase 3 clinical stage, formulation development is required to ensure drug product quality and stability during manufacturing, storage, and clinical administration. During this Q&A, Dr. Jun Lu, Director, Analytical Development at Catalent discusses how Catalent utilizes automation, specifically the UNcle® platform*, during formulation development.

Click here to download article.

The UNcle® Platform is a registered trademark of Unchained Labs.